RxDoctor Payments Data

Charles Lin, MD

Cornea and External Diseases Specialist · Stanford, CANPI 1780818161

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,364 of the $5,044 with a category attached, or 66.7%. 9 manufacturers reported payments, led by Alcon at 57.6% of the total. Reporting peaked in 2020 at $1,969 and has fallen 85.9% since, to $278 in 2025.

$5,044in general payments, 2019–2025

Across 66 payments — averaging $76.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Seagen Inc.$2K
  • Johnson & Johnson Surgical Vision, Inc.$211
  • Oyster Point Pharma, Inc.$70
  • Shire North American Group Inc$56
  • Biotissue Holdings Inc.$43
  • plus $79 from 3 others
$102,887in research payments, 2019–2025

Across 28 payments — averaging $3674.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Kowa Research Institute, Inc.$100K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Shire North American Group Inc$1K

What the payments were for

  • Consulting fees$1,68033%
  • Food & beverage$3,36467%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,044 in reported general payments places this provider in the 55th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$320,775
Medicare patients
533
Services billed
2,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl24$37,437
Prednisolone Acetate427$22,406
Loteprednol Etabonate83$14,550
Fluorometholone66$4,858
Difluprednate26$2,829
ValacyclovirValacyclovir Hcl64$2,568
Brimonidine Tartrate25$2,484
Dorzolamide-TimololDorzolamide/Timolol/Pf14$2,287
MoxifloxacinMoxifloxacin Hcl83$2,005
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,562
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$628
Doxycycline Hyclate25$589
Timolol Maleate43$498
Latanoprost41$444
Ofloxacin20$373

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →